Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China
Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China
复制标题
DOI：
10.1183/09031936.00035114
复制
发表时间：
2015-01-01
影响因子：
24.3
通讯作者：
Zhang, Zhanjun
中科院分区：
文献类型：
--
作者：
Tang, Shenjie;Yao, Lan;Zhang, Zhanjun
利奈唑胺可有效治疗耐多药结核病和广泛耐药结核病。我们进行了一项前瞻性、多中心、随机研究，以进一步评估利奈唑胺在中国广泛耐药结核病患者中的疗效、安全性和耐受性。将65例痰培养阳性的广泛耐药结核病患者随机分配至利奈唑胺治疗组或对照组。两组患者均采用2年个体化化疗方案。利奈唑胺治疗组以1200 mg/d的起始剂量给予利奈唑胺，持续4-6周，然后以300-600 mg/d的剂量给药。利奈唑胺治疗组24个月时痰培养转化的比例为78.8%，显著高于对照组（37.6%，p < 0.01）。
Linezolid may be effective in treating multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. We conducted a prospective, multicentre, randomised study to further evaluate the efficacy, safety and tolerability of linezolid in patients with extensively drug-resistant tuberculosis in China.65 patients who had culture-positive sputum for extensively drug-resistant tuberculosis were randomly assigned to a linezolid therapy group or a control group. Patients in the two groups adopted a 2-year individually based chemotherapy regimen. The linezolid therapy group was given linezolid at a start dose of 1200 mg per day for a period of 4-6 weeks and this was then followed by a dose of 300-600 mg per day.The proportion of sputum culture conversions in the linezolid therapy group was 78.8% by 24 months, significantly higher than that in the control group (37.6%, p